Welcome to the Outcome Measures and Infrastructure for Phase III Studies in Batten Disease, JNCL co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the Office of Rare Diseases Research (ORDR)
The main objective of the meeting is to bring together clinical research experts in JNCL to focus, for the first time, on establishing common ground for outcomes and infrastructure in support of Phase III Clinical Trials. Towards this end, it is anticipated that at the end of the meeting the participants will be able to identify potential clinical trial endpoints for Juvenile Neuronal Ceroid Lipofuscinosis (JNCL, CLN3 disease, Batten Disease); build upon the infrastructure for an International Patient Registry for JNCL and other NCL diseases, and provide opportunities for junior investigators pursuing research in JNCL to learn about and participate in the clinical research development process.
Contact for additional information:
Dr. Danilo Tagle